 Heterocyclic Compounds, 4 or More Rings
"Heterocyclic Compounds, 4 or More Rings" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include four or more fused rings. Both aromatic or non-aromatic ring structures are included in this category.
| Descriptor ID |
D006576
|
| MeSH Number(s) |
D03.633.400
|
| Concept/Terms |
Heterocyclic Compounds, 4 or More Rings- Heterocyclic Compounds, 4 or More Rings
- Heterocyclic Compounds with 4 or More Rings
- Heterocyclic Cpds, 4 or More Rings
- Heterocyclic Compounds with Four or More Rings
Heterocyclic Compounds, 5-Ring- Heterocyclic Compounds, 5-Ring
- 5-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 5 Ring
- Heterocyclic Cpds, 5 Ring
- Five Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Five-Ring
- Fused Heterocyclic Compounds, Five Ring
Heterocyclic Compounds, 4-Ring- Heterocyclic Compounds, 4-Ring
- 4-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 4 Ring
- Heterocyclic Cpds, 4 Ring
- Four Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Four-Ring
- Fused Heterocyclic Compounds, Four Ring
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 4 or More Rings".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 4 or More Rings".
This graph shows the total number of publications written about "Heterocyclic Compounds, 4 or More Rings" by people in this website by year, and whether "Heterocyclic Compounds, 4 or More Rings" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 1 | 3 | | 2016 | 1 | 0 | 1 | | 2017 | 4 | 0 | 4 | | 2018 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Heterocyclic Compounds, 4 or More Rings" by people in Profiles.
-
Meller A, Lotthammer JM, Smith LG, Novak B, Lee LA, Kuhn CC, Greenberg L, Leinwand LA, Greenberg MJ, Bowman GR. Drug specificity and affinity are encoded in the probability of cryptic pocket opening in myosin motor domains. Elife. 2023 01 27; 12.
-
Subbiah V, Bra?a I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 07 01; 28(13):2762-2770.
-
Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology. 2021 06; 73(6):2110-2123.
-
Trigo J, Subbiah V, Besse B, Moreno V, L?pez R, Sala MA, Peters S, Ponce S, Fern?ndez C, Alfaro V, G?mez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Mart?nez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 05; 21(5):645-654.
-
Tengesdal IW, Kitzenberg D, Li S, Nyuydzefe MS, Chen W, Weiss JM, Zhang J, Waksal SD, Zanin-Zhorov A, Dinarello CA. The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6. Eur J Immunol. 2018 10; 48(10):1679-1686.
-
Wyles D, Br?u N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017 Jul 01; 65(1):6-12.
-
Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Liver Int. 2017 12; 37(12):1796-1804.
-
Jackson WE, Everson GT. Sofosbuvir and velpatasvir for the treatment of hepatitis C. Expert Rev Gastroenterol Hepatol. 2017 Jun; 11(6):501-505.
-
Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly ? 2 every-3-week schedule. Invest New Drugs. 2017 08; 35(4):471-477.
-
Chahine EB, Sucher AJ, Hemstreet BA. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. Ann Pharmacother. 2017 Jan; 51(1):44-53.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|